Gilead Sciences Inc. (GILD) belonging to the Medical sector has surged 0.76% and closed its last trading session at $69.06.
The company reported its EPS on 02/07/2017. Currently, the stock has a 1 Year Price Target of $79.1.
The consensus recommendation, according to Zacks Investment research, is 2. The scale runs from 1 to 5 with 1 recommending Strong Buy and 5 recommending a Strong Sell.
The Stock had a 1.85 Consensus Analyst Recommendation 30 Days Ago, whereas 60 days ago and 90 days ago the analyst recommendations were 1.85 and 1.81 respectively.
Gilead Sciences Inc. on 02/07/2017 reported its EPS as $2.7 with the analysts projecting the EPS of the stock as $2.61. The company beat the analyst EPS Estimate with the difference of $0.09. This shows a surprise factor of 3.4%.
Many analysts have provided their estimated foresights on Gilead Sciences Inc. Earnings, with 22 analysts believing the company would generate an Average Estimate of $2.26.
Whereas they predicted High and Low Earnings Estimate as $2.43 and $2.03 respectively. While in the same Quarter Previous year, the Actual EPS was $3.03.
Analysts are also projecting an Average Revenue Estimate for Gilead Sciences Inc. as $6.58 Billion in the Current Quarter. This estimate is provided by 17 analysts.
The High Revenue estimate is predicted as 6.96 Billion, while the Low Revenue Estimate prediction stands at 6.14 Billion. The company’s last year sales total was 7.79 Billion.
For the Current Quarter, the growth estimate for Gilead Sciences Inc. is -25.4%, while for the Next Quarter the stock growth estimate is -30.8%.
In the past 5 years, the stock showed growth of 65.8% per annum. While for the next 5 years, the growth estimate is -4.81%.
The Company got Downgrade by Citigroup on 8-Feb-17 from Buy to Neutral.
Insider Trades for Gilead Sciences Inc. show that the latest trade was made on 28 Feb 2017 where Martin (John C), the Officer and Director completed a transaction type “Sell” in which 73333 shares were traded at a price of $70.38.
47 Insider Sales transactions were made totaling 2536300 shares traded.
22 analysts projected Price Targets for Gilead Sciences Inc.. The analysts believe that the company stock price could grow as high as $95. The Low Price target projection by analysts is $61 and the Mean Price Target is $79.1.
Gilead Sciences Inc. (GILD) has the market capitalization of $90.27 Billion. The company rocked its 52-Week High of $103.1 on Apr 26, 2016 and touched its 52-Week Low of $65.38 on Feb 9, 2017.
The stock has Return on Assets (ROA) of 25.6 percent. Return on Equity (ROE) stands at 83.5% and Return on Investment (ROI) of 31 percent.
The stock is currently showing YTD performance of -2.82 Percent. The company has Beta Value of 1.14 and ATR value of 1.29. The Weekly and Monthly Volatility stands at 1.44% and 1.50%.